These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 24484600)

  • 21. Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery.
    Kumar BS; Saraswathi R; Kumar KV; Jha SK; Venkates DP; Dhanaraj SA
    Drug Deliv; 2014 May; 21(3):173-84. PubMed ID: 24102185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
    Salazar J; Müller RH; Möschwitzer JP
    Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
    Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
    Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery.
    Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
    Int J Pharm; 2011 Nov; 420(1):141-6. PubMed ID: 21884768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical and pharmacokinetic characteristics of different types of fenofibrate nanocrystals prepared by different bottom-up approaches.
    Zhang H; Meng Y; Wang X; Dai W; Wang X; Zhang Q
    Drug Deliv; 2014 Dec; 21(8):588-94. PubMed ID: 24320001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
    Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
    Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baicalin-berberine complex nanocrystals orally promote the co-absorption of two components.
    Li Z; Liu Y; Wang J; Feng X; Nwafor EO; Zhang Y; Liu R; Dang W; Zhang Q; Yu C; Pi J; Liu Z
    Drug Deliv Transl Res; 2022 Dec; 12(12):3017-3028. PubMed ID: 35476182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
    Jain S; Patel K; Arora S; Reddy VA; Dora CP
    Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and Evaluation of Diosgenin Nanocrystals to Improve Oral Bioavailability.
    Liu CZ; Chang JH; Zhang L; Xue HF; Liu XG; Liu P; Fu Q
    AAPS PharmSciTech; 2017 Aug; 18(6):2067-2076. PubMed ID: 27995466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders.
    Du B; Li XT; Zhao Y; A YM; Zhang ZZ
    Pharmazie; 2010 Jul; 65(7):471-6. PubMed ID: 20662313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose-sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin.
    Xie J; Luo Y; Liu Y; Ma Y; Yue P; Yang M
    Int J Nanomedicine; 2019; 14():353-369. PubMed ID: 30655668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K; Narendar D; Kishan V
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies.
    Fu Q; Sun J; Zhang D; Li M; Wang Y; Ling G; Liu X; Sun Y; Sui X; Luo C; Sun L; Han X; Lian H; Zhu M; Wang S; He Z
    Colloids Surf B Biointerfaces; 2013 Sep; 109():161-6. PubMed ID: 23668980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bicalutamide nanocrystals with improved oral bioavailability: in vitro and in vivo evaluation.
    Pokharkar VB; Malhi T; Mandpe L
    Pharm Dev Technol; 2013; 18(3):660-6. PubMed ID: 22394215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
    Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies.
    Dodiya S; Chavhan S; Korde A; Sawant KK
    Drug Dev Ind Pharm; 2013 May; 39(5):733-43. PubMed ID: 22690834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.